Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01690299
First received: September 19, 2012
Last updated: June 27, 2014
Last verified: June 2014

September 19, 2012
June 27, 2014
September 2012
July 2014   (final data collection date for primary outcome measure)
Apremilast Psoriasis Area and Severity Index-75 (PASI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
Proportion of subjects with either apremilast 30 mg twice a day (BID) or placebo who achieve at least a 75% reduction in PASI (PASI-75) at Week 16 from baseline in subjects with plaque type psoriasis or plaque psoriasis
Apremilast Psoriasis Area and Severity Index-75 (PASI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
Proportion of subjects with either apremilast 30 mg twice a day (BID) or placebo who achieve at least a 75% reduction in PASI (PASI-75) at Week 16 from baseline
Complete list of historical versions of study NCT01690299 on ClinicalTrials.gov Archive Site
  • Etanercept Psoriasis Area and Severity Index-75 (PASI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects treated with either etanercept 50mg once weekly (QW) or placebo who achieve PASI-75 (at least a 75% reduction in PASI from baseline in subjects with plaque type psoriasis or plaque psoriasis
  • Disease Severity Score [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects with a Static Physician's Global Assessment (sPGA) of overall disease severity score of clear (0) or almost clear (1) with at least 2 points reduction from baseline in subjects with plaque type psoriasis or plaque psoriasis
  • Percent change from baseline in the body surface area (BSA) affected by psoriasis [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Percent change from baseline in the body surface area (BSA) affected by psoriasis in subjects with plaque type psoriasis or plaque psoriasis
  • Psoriasis Area and Severity Index-50 (PASI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects who achieve PASI-50 (at least a 50% reduction in PASI from baseline) in subjects with plaque type psoriasis or plaque psoriasis
  • Dermatology Life Quality Index (DLQI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Change from baseline in the Dermatology Life Quality Index (DLQI) total score in subjects with plaque type psoriasis or plaque psoriasis
  • Mental Component Summary (MCS) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Change from baseline in the Mental Component Summary (MCS) score of the Medical Outcome Study Short Form 36 - item Health Survey (SF-36) in subjects with plaque type psoriasis or plaque psoriasis
  • Lattice System Physician's Global Assessment (LS-PGA) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects with a Lattice System Physician's Global Assessment (LS-PGA) of psoriasis severity score of clear (0) or almost clear (1) in subjects with plaque type psoriasis or plaque psoriasis
  • Adverse Event [ Time Frame: Week 16 and week 104 ] [ Designated as safety issue: Yes ]
    Number of participants with adverse events in subjects with plaque type psoriasis or plaque psoriasis
  • Etanercept Psoriasis Area and Severity Index-75 (PASI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects treated with either etanercept 50mg once weekly (QW) or placebo who achieve PASI-75 (at least a 75% reduction in PASI from baseline
  • Disease Severity Score [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects with a Static Physician's Global Assessment (sPGA) of overall disease severity score of clear (0) or almost clear (1) with at least 2 points reduction from baseline
  • Percent change from baseline in the body surface area (BSA) affected by psoriasis [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Percent change from baseline in the body surface area (BSA) affected by psoriasis
  • Psoriasis Area and Severity Index-50 (PASI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects who achieve PASI-50 (at least a 50% reduction in PASI from baseline)
  • Dermatology Life Quality Index (DLQI) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Change from baseline in the Dermatology Life Quality Index (DLQI) total score
  • Mental Component Summary (MCS) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Change from baseline in the Mental Component Summary (MCS) score of the Medical Outcome Study Short Form 36 - item Health Survey (SF-36)
  • Lattice System Physician's Global Assessment (LS-PGA) [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
    Proportion of subjects with a Lattice System Physician's Global Assessment (LS-PGA) of psoriasis severity score of clear (0) or almost clear (1)
  • Adverse Event [ Time Frame: Week 16 and week 104 ] [ Designated as safety issue: Yes ]
    Number of participants with adverse events
Not Provided
Not Provided
 
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects With Moderate to Severe Plaque Psoriasis

This study will test the clinical effectiveness and safety of apremilast, etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.

Apremilast (CC-10004) is a new oral agent that is under clinical development for the treatment of inflammatory autoimmune disorders, such as psoriatic arthritis, psoriasis, rheumatoid arthritis, and Behçet disease.

Etanercept is approved for the treatment of psoriasis; it is the most widely prescribed anti-tumor necrosis factor (TNF) for psoriasis.

This is a phase 3b, multicenter, randomized, placebo-controlled, double-blind, double-dummy, study of the efficacy and safety of apremilast, etanercept, and placebo, in subjects with moderate to severe plaque psoriasis.

Approximately 240 subjects will be randomized 1:1:1 to the three treatment groups. All subjects will receive both tablets and injections through Week 16.

The study will consist of four phases:

  • Screening Phase - up to 35 days
  • Double-blind Placebo-controlled Phase - Weeks 0-16
  • Apremilast Extension Phase - Weeks 16-104
  • Post-treatment Observational Follow-up Phase

During the double-blind, placebo-controlled phase, subjects will receive treatment with one of the following:

  • apremilast (APR) 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections (1 mL x 2 injections SC), or
  • etanercept (ETN) 50 mg evaluator/subject-blinded subcutaneous (SC) once weekly (QW) injections (2 x 25 mg) plus placebo tablets orally twice a day (BID), or
  • placebo tablets and evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections.

All subjects will be asked to participate in a 4-week Post-treatment Observational Follow-up Phase either upon completion of the study or upon discontinuation of investigational product for those subjects who terminate the study early.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Psoriasis
  • Psoriatic Arthritis
  • Drug: Apremilast tablet/pill 30 mg
    Apremilast tablet/pill 30 mg tablet orally twice a day
    Other Name: CC-10004
  • Drug: Etanercept 50 mg
    Etanercept 50 mg evaluator/subject-blinded subcutaneous once weekly injection
    Other Name: ETN
  • Drug: Placebo tablet
    Placebo tablets twice a day
    Other Name: Placebo
  • Drug: Placebo injection (saline)
    once weekly evaluator/subject-blinded subcutaneous saline (placebo) injections (1 mL x 2 injections SC)
    Other Name: Placebo
  • Experimental: Apremilast 30 mg plus placebo injection
    Interventions:
    • Drug: Apremilast tablet/pill 30 mg
    • Drug: Placebo injection (saline)
  • Experimental: Etanercept 50 mg plus placebo tablet
    Interventions:
    • Drug: Etanercept 50 mg
    • Drug: Placebo tablet
  • Placebo Comparator: Placebo
    Interventions:
    • Drug: Placebo tablet
    • Drug: Placebo injection (saline)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
250
August 2015
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or females, ≥ 18 years of age
  • Diagnosis of chronic, moderate to severe plaque psoriasis for at least 12 months prior to Screening, and a candidate for phototherapy and/or systemic (including etanercept) therapy
  • Had an inadequate response, intolerance, or contraindication to at least 1 conventional systemic agent for the treatment of psoriasis.
  • No prior exposure to biologics for treatment of psoriatic arthritis or psoriasis

Exclusion Criteria:

  • Other than psoriasis, history of any clinically significant and uncontrolled systemic diseases; any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
  • Pregnant or breast feeding.
  • Have failed more than 3 systemic agents for treatment of psoriasis.
  • History of allergy to any component of the investigational product (IP), including human immunoglobulin (Ig) proteins or allergy to etanercept.
  • Hepatitis B surface antigen or anti-hepatitis C antibody positive at Screening.
  • Latent, active tuberculosis (TB) or inadequately treated TB; nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis, Clostridium difficile).
  • Have a history of, or ongoing, chronic or recurrent infectious disease
  • Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before first administration of IP, or through Week 20 during the study.
  • Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.
  • History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  • Active substance abuse or a history of substance abuse within 6 months prior to Screening.
  • Malignancy or history of malignancy, except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.
  • Psoriasis flare or rebound within 4 weeks prior to Screening.
  • Topical therapy within 2 weeks of randomization or systemic therapy for psoriasis within 4 weeks prior to randomization
  • Use of phototherapy within 4 weeks prior to randomization or prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
  • Any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
  • Prior treatment with apremilast or etanercept.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium,   Canada,   Czech Republic,   Estonia,   Germany,   Hungary,   Latvia,   Netherlands,   United Kingdom
 
NCT01690299
CC-10004-PSOR-010, 2012-000859-14
Yes
Celgene Corporation
Celgene Corporation
Not Provided
Study Director: Lilia Pineda, MD Celgene Corporation
Celgene Corporation
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP